Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of KN 38-7271 in severe traumatic brain injury
2006-001589-17Phase 2Completed
- Sponsor
- KeyNeurotek Pharmaceuticals
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of KN38-7271 in traumatic brain injury (TBI) (3 arms), sponsored by KeyNeurotek Pharmaceuticals. Started Jun 2006; status: completed.
02
Drugs
KN38-7271
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2006-001589-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001589-17.